TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12151286

Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy (CRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control therapy
Number of subjects: 0
Study: 9706934

Group type: EXPERIMENTAL
Intervention: 60 mL of 0.125% bupivacaine
Number of subjects: 42

Group type: COMPARATOR
Intervention: 60 mL of isotonic sodium chloride solution (placebo)
Number of subjects: 42
Study: 7788912

Group type: EXPERIMENTAL
Intervention: 17 beta-Estradiol (2.5 micrograms)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (1 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Intracoronary placebo
Number of subjects: 16
Study: 1693325

Group type: EXPERIMENTAL
Intervention: Dextran prophylaxis
Number of subjects: 176
Study: 371340

Group type: EXPERIMENTAL
Intervention: i.v. tolbutamide after peroral glucose load
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: i.v. glipizide
Number of subjects: 16
Study: 6134490

Group type: EXPERIMENTAL
Intervention: Alclofenac 1 g 3 or 4 times daily
Number of subjects: 27

Group type: COMPARATOR
Intervention: Gold injections 50 mg weekly intramuscularly to 1 g then 50 mg monthly
Number of subjects: 27
Study: 31141104

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 3037

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 3037

Group type: EXPERIMENTAL
Intervention: Clopidogrel (reduced metabolizer status)
Number of subjects: 3037

Group type: EXPERIMENTAL
Intervention: Clopidogrel (prestipulated switching)
Number of subjects: 3037
Study: 29350663

Group type: EXPERIMENTAL
Intervention: Tailored medical support including translated booklets, weekly visits, family-guides, and interpreter-supported clinic visits (Group 1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard protocol (Group 2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tailored medical support (Group 1)
Number of subjects: 40
Study: 27126239

Group type: EXPERIMENTAL
Intervention: Active rESW
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo rESW
Number of subjects: 60
Study: 24293282

Group type: EXPERIMENTAL
Intervention: Community pharmacy‐based intervention for improving adherence to antihypertensive medication
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-reported Morisky scale
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dispensing records
Number of subjects: 0
Study: 22182667

Group type: EXPERIMENTAL
Intervention: Family-focused treatment for prodromal youth (6-month, 18-session intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced care control intervention (3-session psychoeducational intervention)
Number of subjects: 0
Study: 21510531

Group type: EXPERIMENTAL
Intervention: Buffy coat (mesenchymal stem cell concentrate) injection along with arthroscopic debridement
Number of subjects: 50

Group type: COMPARATOR
Intervention: Arthroscopic debridement alone
Number of subjects: 50
Study: 18811927

Group type: EXPERIMENTAL
Intervention: Nurse-led case management home care model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional home care model
Number of subjects: 0
Study: 16135173

Group type: EXPERIMENTAL
Intervention: Intravenous theophylline (200 mg in 200 mL saline) for 2 hours
Number of subjects: 22

Group type: COMPARATOR
Intervention: Saline (200 mL)
Number of subjects: 22
Study: 12424551

Group type: EXPERIMENTAL
Intervention: Stimulant medications (6-month trial)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 10529069

Group type: EXPERIMENTAL
Intervention: Sertraline (50-100 mg/day)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Fluoxetine (20-40 mg/day)
Number of subjects: 286
Study: 7671978

Group type: EXPERIMENTAL
Intervention: High-dose methylprednisolone (1 g MP administered i.v. daily for 5 days followed by oral prednisone tapering over 4 days)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 2074407

Group type: EXPERIMENTAL
Intervention: Standard lateral condensation technique
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Warm lateral condensation technique 1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Warm lateral condensation technique 2
Number of subjects: 60

Group type: COMPARATOR
Intervention: Negative control (4 teeth)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Positive control (2 teeth)
Number of subjects: 60
Study: 6786953

Group type: EXPERIMENTAL
Intervention: 0.25 mg copper daily
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 1.05 mg copper daily
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 1.85 mg copper daily
Number of subjects: 28

Group type: COMPARATOR
Intervention: 1 mg copper daily (fixed dose)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Copper requirements for total parenteral nutrition
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Copper requirements for total parenteral nutrition with diarrhea or increased fluid loss
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Urinary copper excretion
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Plasma copper levels
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Copper infused in excess of requirements
Number of subjects: 28
Study: 30971277

Group type: EXPERIMENTAL
Intervention: SponDT scoring system
Number of subjects: 296
Study: 27579992

Group type: EXPERIMENTAL
Intervention: Telephone-delivered problem-solving treatment (PST)
Number of subjects: 356

Group type: COMPARATOR
Intervention: Education-only (EO)
Number of subjects: 356
Study: 25347016

Group type: EXPERIMENTAL
Intervention: Internet-administered coping skills training program (iCST)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Delayed treatment control (DTC)
Number of subjects: 89
Study: 25050589

Group type: EXPERIMENTAL
Intervention: Submicron diclofenac 35 mg tid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Submicron diclofenac 35 mg bid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21466563

Group type: EXPERIMENTAL
Intervention: Priming materialism
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Exposure to materialistic media
Number of subjects: 155
Study: 18439584

Group type: EXPERIMENTAL
Intervention: GnRH analog for 3 months before surgery
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo for 3 months before surgery
Number of subjects: 20
Study: 17326737

Group type: EXPERIMENTAL
Intervention: Vibration (of the wrist extensor tendons to elicit the illusion of wrist flexion)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Sham (vibration of the ulna styloid)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Active flexion
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Passive flexion
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (no stimulus)
Number of subjects: 22
Study: 15200748

Group type: EXPERIMENTAL
Intervention: Levocetirizine 5 mg od
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg od
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 11450816

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 10068180

Group type: EXPERIMENTAL
Intervention: Dorsoventral one-stage instrumentation with CDI and anterior grafting (group 1)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Anterior CDH instrumentation in combination with anterior grafting (group 2)
Number of subjects: 72
Study: 8177478

Group type: EXPERIMENTAL
Intervention: High-flux cellulose acetate membrane (CA-HF800-E, Diaphan)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cellulose triacetate (CTA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Polysulphone
Number of subjects: 0
Study: 3554963

Group type: EXPERIMENTAL
Intervention: Fat-containing breakfasts (butter or peanut butter)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isocaloric larger carbohydrate meal
Number of subjects: 0
Study: 31636000

Group type: EXPERIMENTAL
Intervention: 2D Gaussian probability density function of rectal motion and wall thickness (2D pdfM&TW)
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: Probability density functions of rectal deformation (DW), rectal dose distribution (RM), and changes in rectal wall thickness (TW)
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: Gaussian mixture distributions for rectal wall thickness
Number of subjects: 587
Study: 30677319

Group type: EXPERIMENTAL
Intervention: Sunflower inbred lines (ILs)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Broad-sense heritability estimates
Number of subjects: 137
Study: 26527863

Group type: EXPERIMENTAL
Intervention: Single oral doses of dicloxacillin sodium (0.25, 0.5, 1.0, and 2.0 g)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Multiple oral doses of dicloxacillin sodium (0.25 or 0.5 g every 6 hours for 3 days)
Number of subjects: 16
Study: 23218455

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee
Number of subjects: 10

Group type: COMPARATOR
Intervention: Decaffeinated coffee
Number of subjects: 10
Study: 21444887

Group type: EXPERIMENTAL
Intervention: REV strategy
Number of subjects: 2364

Group type: COMPARATOR
Intervention: MED strategy
Number of subjects: 2364
Study: 19270315

Group type: EXPERIMENTAL
Intervention: Total arterial revascularization (TAR)
Number of subjects: 331

Group type: COMPARATOR
Intervention: Conventional revascularization (CR)
Number of subjects: 331
Study: 16719030

Group type: EXPERIMENTAL
Intervention: AFO (ankle-foot orthosis)
Number of subjects: 28
Study: 15579913

Group type: EXPERIMENTAL
Intervention: Ifosfamide and cisplatin
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Ifosfamide, cisplatin, and taxanes (paclitaxel or docetaxel)
Number of subjects: 361
Study: 11132503

Group type: EXPERIMENTAL
Intervention: Wand injections
Number of subjects: 62

Group type: COMPARATOR
Intervention: Traditional palatal injection
Number of subjects: 62

Group type: COMPARATOR
Intervention: Traditional buccal injection
Number of subjects: 62
Study: 9358675

Group type: EXPERIMENTAL
Intervention: Antiarrhythmic agents for primary prevention of first episodes in high-risk patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antiarrhythmic agents for secondary prevention in patients who have survived an episode of VT or VF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Identification of high-risk patients for primary prevention
Number of subjects: 0
Study: 7903545

Group type: EXPERIMENTAL
Intervention: Vecuronium 100 micrograms/kg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Pancuronium 100 micrograms/kg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Mixture of vecuronium (50 micrograms/kg) and pancuronium (50 micrograms/kg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 90
Study: 2856769

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Minoxidil
Number of subjects: 15
Study: 30832609

Group type: EXPERIMENTAL
Intervention: LoChro-Care intervention (7 to 16 contacts with chronic care managers within 12 months)
Number of subjects: 606

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 606
Study: 29251010

Group type: EXPERIMENTAL
Intervention: Abaloparatide (80 µg/day) for 18 months followed by Alendronate (70 mg/week) for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo for 18 months followed by Alendronate (70 mg/week) for 6 months
Number of subjects: 0
Study: 26351087

Group type: EXPERIMENTAL
Intervention: Bupi Yishen formula (BYF)
Number of subjects: 554

Group type: COMPARATOR
Intervention: Losartan 100 mg daily
Number of subjects: 554
Study: 23910392

Group type: EXPERIMENTAL
Intervention: Workshop and resources (WS+)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: WS+ and computer assisted training (WS+/CAT)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: WS+/CAT and supervisory support (WS+/CAT/SS)
Number of subjects: 161
Study: 20855349

Group type: EXPERIMENTAL
Intervention: Psilocybin (1-4 oral doses, 45-315 µg/kg body weight)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Psilocybin (high doses)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Psilocybin
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Interpersonal support during adverse reactions
Number of subjects: 110
Study: 20046656

Group type: EXPERIMENTAL
Intervention: Internet-based care management (IBCM) program for diabetes for 1 year
Number of subjects: 104

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: IBCM with sustained usage
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Changes in HbA1c
Number of subjects: 104
Study: 17209189

Group type: EXPERIMENTAL
Intervention: Daily multiple-micronutrient foodLET providing the Recommended Nutrient Intake (RNI) (DMM)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Weekly multiple-micronutrient foodLET providing twice the RNI (WMM)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Daily 10-mg Fe foodLET (DI)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study: 15612858

Group type: EXPERIMENTAL
Intervention: Couples-based coping training (CanCOPE)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Individual coping training for the woman
Number of subjects: 94

Group type: COMPARATOR
Intervention: Medical education control
Number of subjects: 94
Study: 11531839

Group type: EXPERIMENTAL
Intervention: Calcipotriol 0.05 mg g(‐1) cream applied 1 hour before PUVA treatment
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo applied 1 hour before PUVA treatment
Number of subjects: 35
Study: 8155441

Group type: EXPERIMENTAL
Intervention: Mini‐Accelograph (M‐A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Myograph 2000 (MYO)
Number of subjects: 0
Study: 3147186

Group type: EXPERIMENTAL
Intervention: Graves' disease patients
Number of subjects: 24

Group type: COMPARATOR
Intervention: Matched controls (euthyroids)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Methimazole-induced euthyroidism
Number of subjects: 24
Study: 30247010

Group type: EXPERIMENTAL
Intervention: e-book containing information tailored to their disease/injury plus standard consent discussion
Number of subjects: 38

Group type: COMPARATOR
Intervention: standard consent discussion
Number of subjects: 38
Study: 28397079

Group type: COMPARATOR
Intervention: Secukinumab 300 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Secukinumab 150 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 0
Study: 25482999

Group type: EXPERIMENTAL
Intervention: Experimental group (received four in-service workshops and five individualized classroom coaching sessions)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Comparison group (received only the workshops)
Number of subjects: 32
Study: 23474211

Group type: EXPERIMENTAL
Intervention: Isometric exercise
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Isokinetic exercise
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Isotonic exercise
Number of subjects: 61
Study: 21640964

Group type: EXPERIMENTAL
Intervention: Outside-in transobturator tape
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Inside-out transobturator tape
Number of subjects: 83

Group type: COMPARATOR
Intervention: Both interventions (outside-in and inside-out)
Number of subjects: 83
Study: 18845967

Group type: EXPERIMENTAL
Intervention: Bisoprolol 5 mg x d(‐1)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 16412037

Group type: EXPERIMENTAL
Intervention: Regional interventional chemotherapy (infused directly into the common hepatic artery)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Systemic chemotherapy (via peripheral vein)
Number of subjects: 140
Study: 12667511

Group type: EXPERIMENTAL
Intervention: Music exercise group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Occupational therapy group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study: 10892682

Group type: EXPERIMENTAL
Intervention: Cryotherapy (supercooled tonsillar fossa to between -20 degrees C and -32 degrees C for 1 minute)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control (standard post-tonsillectomy care)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control
Number of subjects: 59
Study: 9243241

Group type: EXPERIMENTAL
Intervention: Avoidance of provoking foods
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ingestion of provoking foods
Number of subjects: 15
Study: 8216438

Group type: EXPERIMENTAL
Intervention: LNC‐834 (350 mg of hydrated salt corresponding to 226 mg anhydrous free base each) administered twice daily for 9 days, with warfarin (0.36 +/- 0.03 mg/kg) on the 4th day
Number of subjects: 10

Group type: COMPARATOR
Intervention: Warfarin only (control group)
Number of subjects: 10
Study: 3303905

Group type: EXPERIMENTAL
Intervention: FM plus ICRF‐159 (FMI)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: FM plus triazinate (FMT)
Number of subjects: 165

Group type: COMPARATOR
Intervention: FM plus vincristine (FMV)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 165
Study: 31959047

Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus rhamnosus GG and Bifidobacterium animalis subsp. lactis BB-12) supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Probiotics (Lactobacillus rhamnosus GG and Bifidobacterium animalis subsp. lactis BB-12) not detected
Number of subjects: 0
Study: 28800206

Group type: EXPERIMENTAL
Intervention: Dutasteride/tamsulosin hydrochloride 0.5 mg/0.2 mg fixed-dose combination (FDC1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dutasteride/tamsulosin hydrochloride 0.5 mg/0.2 mg fixed-dose combination (FDC2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dutasteride/tamsulosin hydrochloride 0.5 mg/0.2 mg fixed-dose combination (FDC3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coadministered reference products (1 dutasteride 0.5 mg capsule + 1 tamsulosin hydrochloride 0.2 mg orally disintegrating tablet)
Number of subjects: 0
Study: 27299458

Group type: EXPERIMENTAL
Intervention: Quality of Life Assessment based on Traditional Chinese Medicine (QLASTCM‐Ga)
Number of subjects: 240
Study: 26194172

Group type: EXPERIMENTAL
Intervention: Model 1: Health consultations in general practice during a two-year period
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Model 2: Educational programme for children and families in addition to health consultations
Number of subjects: 80
Study: 24072699

Group type: EXPERIMENTAL
Intervention: Resveratrol (1000 mg daily for week 1 followed by 2000 mg daily for week 2)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 20495134

Group type: COMPARATOR
Intervention: ABT-107 single oral doses (1, 3, 10, 30, 60, 80, and 100 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ABT-107 multiple oral doses (2, 6, and 15 mg once daily for 7 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ABT-107 20-mg single dose (effect of food)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adverse events following single dosing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adverse events following multiple dosing
Number of subjects: 0
Study: 18209514

Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 37

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 37
Study: 16809937

Group type: EXPERIMENTAL
Intervention: Intravenous propionyl-L-carnitine (PLC) 600 mg, 3 times weekly for 12 months
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 12842959

Group type: EXPERIMENTAL
Intervention: New treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current treatment
Number of subjects: 0
Study: 10975160

Group type: EXPERIMENTAL
Intervention: Dyract compomer restoration
Number of subjects: 29

Group type: COMPARATOR
Intervention: Chemfil Superior glass ionomer restoration
Number of subjects: 29
Study: 9208533

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study: 8357293

Group type: EXPERIMENTAL
Intervention: Structured psychiatric group intervention
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study: 3768223

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 15

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 15

Group type: COMPARATOR
Intervention: Enflurane
Number of subjects: 15
Study: 29897821

Group type: EXPERIMENTAL
Intervention: High-repetition/low-load resistance training (20-25 repetitions, 30-50% of 1RM)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low-repetition/high-load resistance training (8-12 repetitions, 75-90% of 1RM)
Number of subjects: 20
Study: 29231568

Group type: EXPERIMENTAL
Intervention: Drug-spreading moxibustion
Number of subjects: 101

Group type: COMPARATOR
Intervention: Meloxicam (7.5 mg once a day for three days)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Meloxicam
Number of subjects: 101
Study: 25514543

Group type: EXPERIMENTAL
Intervention: Zuclopenthixol (doses <10 mg/day)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 22382340

Group type: EXPERIMENTAL
Intervention: Stanford Arthritis Self-Management Program (ASMP) and self-help book
Number of subjects: 120

Group type: COMPARATOR
Intervention: Book only (Control)
Number of subjects: 120
Study: 20131142

Group type: EXPERIMENTAL
Intervention: Fatigue condition (five bouts of great toe curls at 60% one-repetition maximum to failure)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control condition (resting in a supine position for 30 min)
Number of subjects: 16
Study: 18311826

Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 16451371

Group type: EXPERIMENTAL
Intervention: Fluoride toothpaste brushing after exposure to soft drinks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water brushing after exposure to soft drinks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-fluoride toothpaste brushing after exposure to soft drinks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluoride toothpaste slurry after exposure to soft drinks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brushing alone (control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Soft drinks (OJ, CC, MB) alone
Number of subjects: 0